ESC 365 - The effect of intravenous ferric-carboxymaltose on cardiac reverse remodeling following cardiac resynchronization therapy - The IRON CRT trial.

HFA Premium Access

The effect of intravenous ferric-carboxymaltose on cardiac reverse remodeling following cardiac resynchronization therapy - The IRON CRT trial.

Session: Late-Breaking Trials 1

Topic: Pharmacotherapy

Speaker: Doctor P. Martens (Genk, BE)

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Doctor Pieter Martens

Hospital Oost-Limburg (ZOL), Genk (Belgium)

3 presentations

0 follower

2 more presentations in this session

Influence of Atrial Fibrillation on Efficacy of Omecamtiv Mecarbil in Heart Failure: The GALACTIC-HF Trial

Speaker: Professor S. Solomon (Boston, US)

Finerenone in patients with chronic kidney disease and type 2 diabetes, with and without a history of heart failure: a secondary analysis of the FIDELIO-DKD trial

Speaker: Professor G. Filippatos (Athens, GR)

Access the full session

Late-Breaking Trials 1

Speakers: Doctor P. Martens, Professor S. Solomon, Professor G. Filippatos

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources